Browse Options
Can a basic patent be amended under Art. 138.3 EPC to overcome a nullity action brought against its SPC?

The messy case law from the Court of Justice of the European Union (“CJEU”) on supplementary protection certificates (“SPC”) that protect “combinations” of pharmaceutical products has left many patentees that relied in good faith on the criteria laid down by the CJEU in the judgment of 16 September 1999, Case C-392/97 (“Farmitalia”) with patents whose claims are not totally aligned with the new criteria laid down in the judgment of 24 November 2011, Case C-322/10 (“Medeva”), and the ensuing saga. Readers will remember that in Farmitalia the CJEU responded that it was not for the CJEU but for national courts to determine whether or not a product is protected by the basic patent. This was cohe [...]

The CJEU rulings of 30 January 2014 on TRIPS: If you don’t want to get the wrong answer, don’t ask the wrong question

On 30 January 2014 the Court of Justice of the European Union (“CJEU”) handed down two Decisions in response to two preliminary rulings sought by the same Greek Court that referred the questions answered by the CJEU in its Judgment of 18 July 2013 (Case C‑414/11, Daiichi Sankyo Co. Ltd, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon). In this case, the Greek Court, which was hearing a matter involving a patent that had been granted on 21 October 1986, sought the guidance of the CJEU on whether under Articles 27 and 70 of the TRIPs Agreement a patent protecting a process to obtain a pharmaceutical product would protect the product as such after t [...]

An expert must be an expert

On 22 October 2013 the Provincial Court of Barcelona (Section 15) handed down a controversial judgment revoking a patent due to lack of inventive activity relying on a technical report prepared by an expert acknowledged not to be an expert in the technical field of the invention. According to the judgment “[...] for an expert to be able to provide the point of view of the person skilled in the art – necessary in this case to assess the inventive activity -, it is not essential for the expert to be an expert but that, due to his training and experience, he is capable of putting himself in the position of the «person skilled in the art».” 

This point of view is at odds with the conclusio [...]

UPC: 16th draft of Rules of Procedure unveiled yesterday. The obstinate “opting-out” fee: will those who sow the wind, reap the whirlwind?

UPC aficionados will be interested to learn that the 16th draft of the Rules of Procedure was unveiled yesterday.

Readers will remember that the previous draft was published on 31 May 2013. Since then, the Drafting Committee has been working on a new draft that may – or may not – accommodate the comments received from stakeholders, including those discussed at the European Judge’s Forum that took place in Venice on 25-26 October 2013. Trying to comment on the 382 Rules of the draft in this very brief blog would be like trying to sum-up the history of mankind in a haiku. So this author will focus his attention on one aspect that appears to be here to stay: the obstinate “opting-out” fee. [...]

Spanish Supreme Court clarifies that its case law on TRIPS is not affected by the ECJ Daiichi Judgment

The readers will recall that on 18 July 2013, the European Court of Justice (“ECJ”) handed down its controversial judgment in case C‑414/11 Daiichi Sankyo Co. Ltd, Sanofi-Aventis Deutschland GmbH v. DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon. In this judgment the ECJ, making a 180º twist in relation to the criteria endorsed in Opinion 1/1994, in its judgment of 14 December 2000 and in its judgment of 11 September 2007, concluded that TRIPS’ provisions on patents now fall within the realm of the European Union (“EU”) common commercial policy. This is a rather surprising conclusion to reach, taking into account that in paragraph 46 of its judgment of 11 September 2007 the ECJ [...]

Levonorgestrel, Court of Appeal of Burgos, 2 September 2013

The Court of Appeal of Burgos dismissed the appeal against the Judgment of the Provincial Court of Burgos, which upheld a patent for a pharmaceutical composition and its use, despite the fact that clinical trials regarding the patented composition and the patented use were mentioned in the prior art.

The full summary of this case has been posted on Kluwer IP Law.

Contributors, Authors, Books, & More...